2 hours ago | News
Veloxis Pharmaceuticals A/S today announced that it contemplates restructuring the company's operations in order to fully focus its resources on the completion of the development and subsequent commercialization of LCP-TacroT, Veloxis' product candidate for the prevention of organ rejection.
|
3 hours ago | News
Pfizer Inc. named Olivier Brandicourt as President and General Manager of the Emerging Markets and Established Products Business Units, effective June 1, 2012.
|
3 hours ago | News
Pharmaceutical Product Development, LLC (PPD) today announced that its board of directors has named David Simmons chairman and CEO.
|
23 hours ago | News
InterMune, Inc. today announced that it has reached a definitive agreement with Vidara Therapeutics International Limited to sell its rights to Actimmune® (interferon gamma-1b) in a cash transaction valued at $55 million plus a two-year royalty stream.
|
May 22 | News
AMRI, a global contract research and manufacturing organization, announced today the appointment of Ian Shott as President of AMRI Europe, reporting to Thomas D'Ambra, Ph.D., chairman, president and CEO.
|
May 22 | News
NEW YORK (AP) — Standard & Poor's Indices said Monday that it is adding the stock of drug developer Alexion Pharmaceuticals Inc. to its S&P 500 index.
|
May 21 | News
Ross announces the completion of a large order totaling fifty-one (51) High Speed Dispersers for installation at two facilities of a multinational company.
|
May 21 | News
Marina Biotech, Inc., a leading nucleic acid-based drug discovery and development company, and Girindus Group today announced that they have entered into a strategic alliance where Girindus will have exclusive rights to develop, supply and commercialize certain oligonucleotide constructs using Marina's Conformationally Restricted Nucleotide (CRN) chemistry and in return, Marina will receive royalties from the sale of CRN-based oligonucleotide reagents as well as a robust supply of cGMP material for Marina and its partners' pre-clinical, clinical and commercialization needs.
|
May 18 | News
LONDON (AP) — GlaxoSmithKline says it will persist with its bid to take over U.S. company Human Genome Sciences despite the target's new 'poison pill' defense.
|
May 17 | News
NEW YORK (AP) — Alkermes PLC said today it took a larger loss in its fiscal fourth quarter after it acquired a drug technology business and took a one-time charge related to research and development.
|